Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,025 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02158234 | Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT05472220 | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | Dec 27, 2022 |
| clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | withdrawn | Phase 1 | 0 | Instil BioINDUSTRY | 0 | Dec 20, 2022 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma | terminated | Phase 1 | 7 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT03129061 | Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN) | completed | Phase 1 | 15 | CellSight Technologies, Inc.INDUSTRY | 1 | Dec 5, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT02764593 | Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer | completed | Phase 1 | 40 | RTOG Foundation, Inc.OTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | terminated | Phase 1 | 30 | AmgenINDUSTRY | 5 | Nov 8, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT03502148 | Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma(PRV111) | completed | Phase 1 / Phase 2 | 10 | Privo TechnologiesINDUSTRY | 1 | Oct 21, 2022 | clinicaltrials |
| NCT05027204 | A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) | unknown | Phase 1 / Phase 2 | 94 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05552807 | SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | unknown | Phase 1 | 120 | Sinocelltech Ltd.INDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT01592721 | Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 6 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05541445 | Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC | unknown | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT00470496 | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer | completed | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02531906 | Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation | completed | Phase 1 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT02775812 | Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 10, 2022 | clinicaltrials |
| NCT04293679 | Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC | completed | Phase 1 / Phase 2 | 25 | SirnaomicsINDUSTRY | 1 | Jun 9, 2022 | clinicaltrials |
| NCT05394415 | Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC(LATE) | unknown | Phase 1 / Phase 2 | 30 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT04213404 | Ribociclib and Spartalizumab in R/M HNSCC(RISE-HN) | unknown | Phase 1 | 13 | National Taiwan University HospitalOTHER | 1 | Apr 21, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Silverback TherapeuticsINDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT05317325 | A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC | unknown | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT03278626 | Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 12 | NYU Langone HealthOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT03799744 | Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma | unknown | Phase 1 | 20 | Institut Català d'OncologiaOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05299203 | BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma) | unknown | Phase 1 | 18 | West China HospitalOTHER | 0 | Mar 28, 2022 | clinicaltrials |
| NCT03458117 | T-VEC in Non-melanoma Skin Cancer(20139157 T-VEC) | completed | Phase 1 | 26 | University of ZurichOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT02178072 | Window Trial 5-aza in HNSCC, T-tare | completed | Phase 1 | 18 | Yale UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT02901483 | A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 12 | PharmaEngineINDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT01332266 | E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 95 | Eisai Inc.INDUSTRY | 4 | Jan 3, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT04506138 | Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 46 | Zhejiang Cancer HospitalOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT02915432 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | unknown | Phase 1 / Phase 2 | 401 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT05117138 | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors | unknown | Phase 1 / Phase 2 | 39 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Nov 11, 2021 | clinicaltrials |
| NCT02636036 | Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors(SPICE) | completed | Phase 1 | 51 | Akamis BioINDUSTRY | 1 | Nov 9, 2021 | clinicaltrials |
| NCT00660218 | A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer | completed | Phase 1 / Phase 2 | 53 | State University of New York - Upstate Medical UniversityOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT03291002 | Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC | unknown | Phase 1 | 98 | CureVacINDUSTRY | 5 | Nov 4, 2021 | clinicaltrials |
| NCT03100045 | Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)(ART-AIN) | completed | Phase 1 | 18 | Johns Hopkins UniversityOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jan 19, 2023source: clinicaltrials